We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG's Vessel Sealer Curved for da Vinci Systems Gets FDA Approval
Read MoreHide Full Article
Key Takeaways
ISRG received FDA clearance for its Vessel Sealer Curved, expanding its da Vinci surgical instrument lineup.
ISRG's new tool performs four functions in one, improving control and efficiency in tight anatomical spaces.
ISRG enhanced the design with better visibility and versatility, plus clearance to transect lymphatic vessels.
Intuitive Surgical (ISRG - Free Report) recently received FDA clearance for its Vessel Sealer Curved, a multifunctional instrument designed for use with compatible da Vinci surgical systems. The Vessel Sealer Curved enables surgeons to grasp, dissect, coagulate, and transect tissue using a single, wristed tool, improving procedural efficiency in minimally invasive surgeries.
The new instrument integrates Intuitive Surgical’s advanced bipolar energy technology with refined mechanical design to enhance performance and precision in robotic-assisted surgeries. This clearance expands Intuitive Surgical’s portfolio of surgical tools and reinforces its commitment to delivering innovative solutions that help improve outcomes and streamline operating room workflows.
Likely Trend of ISRG Stock Following the News
Following the announcement, the company's shares traded flat until yesterday’s closing. Shares have lost 1.8% in the year-to-date period compared with the industry’s 11.5% decline. The S&P 500 has gained 5.6% in the same time frame.
The FDA clearance of the Vessel Sealer Curved enhances Intuitive Surgical’s value proposition by adding a versatile, high-precision instrument to its da Vinci ecosystem. Its ability to perform multiple functions in tight anatomical spaces can increase procedural efficiency and broaden the appeal of robotic-assisted surgery across specialties. Over time, this can drive higher procedure volumes, strengthen recurring revenue from instrument sales, and deepen hospital and surgeon reliance on the da Vinci platform, supporting long-term business growth.
ISRG currently has a market capitalization of $183.59 billion. It has an earnings yield of 1.45%, higher than the industry’s negative 2.88%. In the last reported quarter, ISRG delivered an earnings surprise of 5.85%.
Image Source: Zacks Investment Research
More on ISRG’s Vessel Sealer Curved
Vessel Sealer Curved is a fully wristed, advanced bipolar electrosurgical instrument developed by Intuitive Surgical for use with compatible da Vinci systems. It is designed to seal, cut, grasp, and dissect tissue, offering multifunctionality in a single tool. It is the first advanced energy instrument from Intuitive Surgical to receive FDA clearance for the transection of lymphatic vessels, as well as its use in bipolar coagulation and mechanical transection of blood vessels up to 7mm in diameter, tissue bundles, and lymphatic structures. The device is not indicated for tubal sterilization or tubal coagulation procedures.
Engineered for precision in confined anatomical spaces, the instrument features a slim, curved jaw that follows natural anatomical contours, improving visibility and control near critical structures. Its mechanical blade, positioned closer to the tip, enhances the device’s versatility as a dissector. The new design builds on the trusted performance of Vessel Sealer Extend, offering improved access and surgical control.
More on ISRG’s da Vinci Surgical Systems
Intuitive Surgical’s da Vinci platform has become a cornerstone of robotic-assisted surgery, with nearly 17 million procedures performed globally since its inception. The company has trained approximately 90,000 surgeons to operate its systems, reflecting widespread adoption and trust in its technology.
With each innovation, including the addition of advanced instruments like the Vessel Sealer Curved, Intuitive Surgical continues to strengthen the capabilities of the da Vinci ecosystem, supporting its long-term mission to improve patient outcomes, enhance the surgical experience, and lower the total cost of care.
Favorable Industry Prospects for ISRG
Per a report by Grand View Research, the global surgical robots market size was estimated at $4.31 billion in 2024 and is projected to reach $7.42 billion by 2030, registering a CAGR of 9.42% from 2025 to 2030.
Industry growth is driven by technological innovation, increasing investments from global and regional players, as well as a rise in chronic conditions and joint replacement procedures.
ISRG’s Zacks Rank & Other Key Picks
Currently, ISRG carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Hims & Hers Health, Inc. (HIMS - Free Report) , Cencora, Inc. (COR - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
Hims & Hers, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 36.5%. HIMS’ earnings surpassed estimates in two of the trailing four quarters, missed once and met in the other, the average surprise being 19.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hims & Hers’ shares have surged 99.2% compared with the industry’s 37.1% growth in the past year.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%.
Cencora’s shares have rallied 23.9% against the industry’s 16.9% decline in the past year.
Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
Integer Holdings’ shares have gained 4.9% against the industry’s 13% decline in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ISRG's Vessel Sealer Curved for da Vinci Systems Gets FDA Approval
Key Takeaways
Intuitive Surgical (ISRG - Free Report) recently received FDA clearance for its Vessel Sealer Curved, a multifunctional instrument designed for use with compatible da Vinci surgical systems. The Vessel Sealer Curved enables surgeons to grasp, dissect, coagulate, and transect tissue using a single, wristed tool, improving procedural efficiency in minimally invasive surgeries.
The new instrument integrates Intuitive Surgical’s advanced bipolar energy technology with refined mechanical design to enhance performance and precision in robotic-assisted surgeries. This clearance expands Intuitive Surgical’s portfolio of surgical tools and reinforces its commitment to delivering innovative solutions that help improve outcomes and streamline operating room workflows.
Likely Trend of ISRG Stock Following the News
Following the announcement, the company's shares traded flat until yesterday’s closing. Shares have lost 1.8% in the year-to-date period compared with the industry’s 11.5% decline. The S&P 500 has gained 5.6% in the same time frame.
The FDA clearance of the Vessel Sealer Curved enhances Intuitive Surgical’s value proposition by adding a versatile, high-precision instrument to its da Vinci ecosystem. Its ability to perform multiple functions in tight anatomical spaces can increase procedural efficiency and broaden the appeal of robotic-assisted surgery across specialties. Over time, this can drive higher procedure volumes, strengthen recurring revenue from instrument sales, and deepen hospital and surgeon reliance on the da Vinci platform, supporting long-term business growth.
ISRG currently has a market capitalization of $183.59 billion. It has an earnings yield of 1.45%, higher than the industry’s negative 2.88%. In the last reported quarter, ISRG delivered an earnings surprise of 5.85%.
Image Source: Zacks Investment Research
More on ISRG’s Vessel Sealer Curved
Vessel Sealer Curved is a fully wristed, advanced bipolar electrosurgical instrument developed by Intuitive Surgical for use with compatible da Vinci systems. It is designed to seal, cut, grasp, and dissect tissue, offering multifunctionality in a single tool. It is the first advanced energy instrument from Intuitive Surgical to receive FDA clearance for the transection of lymphatic vessels, as well as its use in bipolar coagulation and mechanical transection of blood vessels up to 7mm in diameter, tissue bundles, and lymphatic structures. The device is not indicated for tubal sterilization or tubal coagulation procedures.
Engineered for precision in confined anatomical spaces, the instrument features a slim, curved jaw that follows natural anatomical contours, improving visibility and control near critical structures. Its mechanical blade, positioned closer to the tip, enhances the device’s versatility as a dissector. The new design builds on the trusted performance of Vessel Sealer Extend, offering improved access and surgical control.
More on ISRG’s da Vinci Surgical Systems
Intuitive Surgical’s da Vinci platform has become a cornerstone of robotic-assisted surgery, with nearly 17 million procedures performed globally since its inception. The company has trained approximately 90,000 surgeons to operate its systems, reflecting widespread adoption and trust in its technology.
With each innovation, including the addition of advanced instruments like the Vessel Sealer Curved, Intuitive Surgical continues to strengthen the capabilities of the da Vinci ecosystem, supporting its long-term mission to improve patient outcomes, enhance the surgical experience, and lower the total cost of care.
Favorable Industry Prospects for ISRG
Per a report by Grand View Research, the global surgical robots market size was estimated at $4.31 billion in 2024 and is projected to reach $7.42 billion by 2030, registering a CAGR of 9.42% from 2025 to 2030.
Industry growth is driven by technological innovation, increasing investments from global and regional players, as well as a rise in chronic conditions and joint replacement procedures.
ISRG’s Zacks Rank & Other Key Picks
Currently, ISRG carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Hims & Hers Health, Inc. (HIMS - Free Report) , Cencora, Inc. (COR - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
Hims & Hers, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 36.5%. HIMS’ earnings surpassed estimates in two of the trailing four quarters, missed once and met in the other, the average surprise being 19.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hims & Hers’ shares have surged 99.2% compared with the industry’s 37.1% growth in the past year.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%.
Cencora’s shares have rallied 23.9% against the industry’s 16.9% decline in the past year.
Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
Integer Holdings’ shares have gained 4.9% against the industry’s 13% decline in the past year.